Search

Your search keyword '"Skovronsky DM"' showing total 67 results

Search Constraints

Start Over You searched for: Author "Skovronsky DM" Remove constraint Author: "Skovronsky DM"
67 results on '"Skovronsky DM"'

Search Results

1. The Centiloid project: Standardizing quantitative amyloid plaque estimation by PET

2. Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study

3. Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study

4. Cognition and amyloid load in Alzheimer disease imaged with florbetapir F 18(AV-45) positron emission tomography.

6. Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue.

7. Use of florbetapir-PET for imaging beta-amyloid pathology.

8. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.

9. A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load.

10. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.

11. Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial.

12. Donanemab in Early Alzheimer's Disease.

13. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.

14. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.

16. Effect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criteria.

17. A Semiautomated Method for Quantification of F 18 Florbetapir PET Images.

18. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.

19. Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study.

20. PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders.

21. Radiation dosimetry of florbetapir F 18.

22. Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates.

23. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging.

24. Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals.

25. Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline.

26. Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease.

27. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study.

28. In vivo imaging of endogenous pancreatic β-cell mass in healthy and type 1 diabetic subjects using 18F-fluoropropyl-dihydrotetrabenazine and PET.

29. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.

30. Differential diagnosis in Alzheimer's disease and dementia with Lewy bodies via VMAT2 and amyloid imaging.

31. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.

32. Sigma receptor binding of tetrabenazine series tracers targeting VMAT2 in rat pancreas.

33. In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer disease.

34. Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent.

35. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18).

36. Binding characteristics of 9-fluoropropyl-(+)-dihydrotetrabenzazine (AV-133) to the vesicular monoamine transporter type 2 in rats.

37. (18)F-AV-133: A Selective VMAT2-binding Radiopharmaceutical for PET Imaging of Dopaminergic Neurons.

38. The use of the exploratory IND in the evaluation and development of 18F-PET radiopharmaceuticals for amyloid imaging in the brain: a review of one company's experience.

39. Synthesis and evaluation of indolinyl- and indolylphenylacetylenes as PET imaging agents for beta-amyloid plaques.

40. Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications.

41. Pathologic classification of peripheral nerve tumors.

42. Iodinated tracers for imaging amyloid plaques in the brain.

43. Secretion and intracellular generation of truncated Abeta in beta-site amyloid-beta precursor protein-cleaving enzyme expressing human neurons.

44. Detection of amyloid plaques by radioligands for Abeta40 and Abeta42: potential imaging agents in Alzheimer's patients.

45. Radioiodinated styrylbenzene derivatives as potential SPECT imaging agents for amyloid plaque detection in Alzheimer's disease.

46. Neuronal localization of the TNFalpha converting enzyme (TACE) in brain tissue and its correlation to amyloid plaques.

47. Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates.

48. Amyloid precursor protein and amyloid beta peptide in human platelets. Role of cyclooxygenase and protein kinase C.

49. In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease.

Catalog

Books, media, physical & digital resources